Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (28649)	4/2/1999 10:20:00 PM
From: Cacaito	Respond to of 32384

Targretin phase II trial for advanced Tamoxifen resistant tumors began in November 1998, is ongoing and has an expected recruitment of 180 patients. There were some comments before suggesting it was completed, results not given to the public and all this due to probably poor results. This is not true. (my view from reading the 10K). How long will this trial last? Results? the least duration is one year (my view), in advanced cancer the drug should showed some survival improvement at least of several months more than expected. Shorcuts to show some efficacy are improved quality of life (less pain, less complications)decrease in tumor size, decrease in metastasis could provide earlier results.